Bipolar disorder, currently in remission, most recent episode unspecified
Methodology & AI Transparency ⓘ
Bipolar disorder, currently in remission, most recent episode unspecified Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Bipolar disorder, currently in remission, most recent episode unspecified (ICD-10-CM F31.70), Depression, Bipolar & Mood Disorders protocols prioritize medical mimic exclusion in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: (thyroid) paired with baseline and interval TSH & Free in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: T4 Rule-Out) assessment.
- 2 Real-world patient consensus: Federal ICD-10-CM code F31.70 categorizes Bipolar disorder, currently in remission, most recent episode unspecified under Depression, Bipolar & Mood Disorders.
- 3 Typical cash cost range: Primary evaluation for Bipolar disorder, currently in remission, most recent episode unspecified incorporates medical mimic exclusion in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: (thyroid) and symptom diary review.
- 4 Top reported side effects / signs: Key Depression & Mood biomarkers for Bipolar disorder, currently in remission, most recent episode unspecified (F31.70): TSH & Free in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: T4 Rule-Out) & Serum Vitamin D in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: & RBC Folate) (25(OH)D 40 – 65 ng/mL (F31.70)).
Ask our AI Specialists anything about Bipolar disorder, currently in remission, most recent episode unspecified
What Is Bipolar disorder, currently in remission, most recent episode unspecified?
For patients presenting with Bipolar disorder, currently in remission, most recent episode unspecified (ICD-10-CM F31.70), Depression, Bipolar & Mood Disorders protocols prioritize medical mimic exclusion in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: (thyroid) paired with baseline and interval TSH & Free in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: T4 Rule-Out) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Bipolar disorder, currently in remission, most recent episode unspecified (F31.70, Depression & Mood) reflects stress-induced BDNF reduction [Bipolar disorder, currently in remission, most recent episode unspecified F31.70]. longitudinal control is benchmarked via TSH & Free in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: T4 Rule-Out).
Common Symptoms & Clinical Signs
- • Presentation of Bipolar disorder, currently in remission, most recent episode unspecified (F31.70): loss of interest in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: or pleasure in)
- • Secondary Bipolar disorder, currently in remission, most recent episode unspecified clinical sign: persistent low mood, in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: emotional flatness, or)
- • Symptom flares in Bipolar disorder, currently in remission, most recent episode unspecified correlating with TSH & Free in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: T4 Rule-Out) deviation outside TSH 0.8 – 2.5 mIU/L (F31.70)
- • Functional depression & mood impact requiring medical mimic exclusion in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: (thyroid) evaluation (F31.70)
Bipolar disorder, currently in remission, most recent episode unspecified Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F31.70 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: TSH & Free in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F31.70) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Vitamin D in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F31.70) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Bipolar disorder, currently in remission, most recent episode unspecified (F31.70: Score) | < 4 (clinical remission) (F31.70) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Bipolar disorder, currently in remission, most recent episode unspecified
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Daunorubicin Hydrochloride Daunorubicin Hydrochloride Generic • RxCUI 309650 | Anthracycline Topoisomerase Inhibitor | 76% | $2.8100 | $ 122.31 /mo |
| Arsenic Trioxide Arsenicum Album, Arsenicum Album 30c • RxCUI 829926 | FDA Prescription Therapeutic Agent | 79% | $3.3900 | $ 145.80 /mo |
| Thioguanine Tabloid • RxCUI 105590 | Antimetabolite | 91% | $0.6300 | $ 34.02 /mo |
| Mesalamine Rowasa, Lialda • RxCUI 825130 | Aminosalicylate | 80% | $0.4196 | $ 27.63 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Bipolar disorder, currently in remission, most recent episode unspecified)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Efficacy of Lumateperone in Patients With Bipolar Depression With Mixed: What a 376-Participant Study Found Conclusions: Lumateperone 42 mg significantly improved symptoms of depression and disease severity in patients with an MDE associated with bipolar I or bipolar II disorder, with or without mixed features. The Journal of clinical psychiatry • 2023-04-24 • Phase III Randomized Trial | N = 376 | 93/100 | PMID 37103915 ↗ |
| Can This Approach Help? Inside the Latest Research on Increased global integration in the brain after psilocybin therapy for The antidepressant response to escitalopram was milder and no changes in brain network organization were observed. Nature medicine • 2022-04-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 35411074 ↗ |
| New Insights on Exercise and pharmacotherapy in the treatment of: What a 202-Participant Study Found The efficacy of exercise in patients seems generally comparable with patients receiving antidepressant medication and both tend to be better than the placebo in patients with MDD. Psychosomatic medicine • 2007-01-15 • Randomized Controlled Trial | N = 202 | 88/100 | PMID 17846259 ↗ |
| Can This Approach Help? Inside the Latest Research on Duration of Adjunctive Antidepressant Maintenance in Bipolar I In a trial involving patients with bipolar I disorder and a recently remitted depressive episode, adjunctive treatment with escitalopram or bupropion XL that continued for 52 weeks did not show a significant benefit as... The New England journal of medicine • 2023-08-03 • Randomized Controlled Trial | N = 90 | 88/100 | PMID 37530824 ↗ |
| Can This Approach Help? Inside the Latest Research on Improvement in Depression is Associated with Improvement in Cognition in Cognitive dysfunction was not a detriment to improvement in symptoms of psychotic major depression in our older adults patients. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry • 2017-06-15 • Randomized Controlled Trial | N = 71 | 88/100 | PMID 28285771 ↗ |
Bipolar disorder, currently in remission, most recent episode unspecified Patient Community & “People Like Me” Threads
Filter Bipolar disorder, currently in remission, most recent episode unspecified community threads and patient logs by age, biological sex, dosage, and treatment duration.